BRPI0813139A2 - Peptídeo glp-1 com adição de uma cadeia oligossacarídea - Google Patents

Peptídeo glp-1 com adição de uma cadeia oligossacarídea

Info

Publication number
BRPI0813139A2
BRPI0813139A2 BRPI0813139-2A2A BRPI0813139A BRPI0813139A2 BR PI0813139 A2 BRPI0813139 A2 BR PI0813139A2 BR PI0813139 A BRPI0813139 A BR PI0813139A BR PI0813139 A2 BRPI0813139 A2 BR PI0813139A2
Authority
BR
Brazil
Prior art keywords
oligosacaride
glp
peptide
chain
addition
Prior art date
Application number
BRPI0813139-2A2A
Other languages
English (en)
Inventor
Yasuhiro Kajihara
Izumi Sakamoto
Takashi Tsuji
Yuri Nambu
Kazuhiro Fukae
Katsunari Tezuka
Hiroaki Asai
Original Assignee
Otsuka Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Chemical Co Ltd filed Critical Otsuka Chemical Co Ltd
Publication of BRPI0813139A2 publication Critical patent/BRPI0813139A2/pt
Publication of BRPI0813139A8 publication Critical patent/BRPI0813139A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BRPI0813139A 2007-06-19 2008-06-17 peptídeo glp-1 com adição de cadeia oligossacarídea BRPI0813139A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007160951 2007-06-19
PCT/JP2008/001554 WO2008155900A1 (ja) 2007-06-19 2008-06-17 糖鎖付加glp-1ペプチド

Publications (2)

Publication Number Publication Date
BRPI0813139A2 true BRPI0813139A2 (pt) 2015-02-18
BRPI0813139A8 BRPI0813139A8 (pt) 2019-01-29

Family

ID=40156064

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813139A BRPI0813139A8 (pt) 2007-06-19 2008-06-17 peptídeo glp-1 com adição de cadeia oligossacarídea

Country Status (13)

Country Link
US (3) US7985731B2 (pt)
EP (1) EP2172479B1 (pt)
JP (1) JP5646848B2 (pt)
KR (1) KR20100049032A (pt)
CN (1) CN102015761A (pt)
AU (1) AU2008264750C1 (pt)
BR (1) BRPI0813139A8 (pt)
CA (1) CA2696615A1 (pt)
DK (1) DK2172479T3 (pt)
RU (1) RU2539829C2 (pt)
SG (1) SG178797A1 (pt)
TW (1) TWI423821B (pt)
WO (1) WO2008155900A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0813139A8 (pt) * 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea
BRPI0914889A2 (pt) * 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
CA2778890A1 (en) * 2009-10-30 2011-05-05 Otsuka Chemical Co., Ltd. Glycosylated form of antigenic glp-1 analogue
US9234023B2 (en) * 2010-06-24 2016-01-12 Biousian Biosystems, Inc. Glucagon-like peptide-1 glycopeptides
WO2012086811A1 (ja) * 2010-12-22 2012-06-28 味の素株式会社 摂食抑制剤及び抗肥満剤
CN102718858B (zh) * 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
BR112014004784A2 (pt) * 2011-09-04 2017-03-21 Glytech Inc polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
CN102321170B (zh) * 2011-09-14 2013-11-13 深圳翰宇药业股份有限公司 利拉鲁肽变构体及其缀合物
IN2014CN02982A (pt) * 2011-10-01 2015-07-03 Glytech Inc
JP6211533B2 (ja) * 2012-11-22 2017-10-11 株式会社糖鎖工学研究所 糖鎖付加リンカー、糖鎖付加リンカー部分と生理活性物質部分とを含む化合物またはその塩、及びそれらの製造方法
CN104936613B (zh) * 2012-11-30 2018-05-22 株式会社糖锁工学研究所 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
AU2014245917B2 (en) * 2013-03-29 2017-09-28 Glytech, Inc. Polypeptide having sialylated sugar chains attached thereto
KR102291020B1 (ko) 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
CN122440793A (zh) 2016-06-29 2026-07-24 韩美药品株式会社 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
WO2021029698A1 (ko) * 2019-08-13 2021-02-18 애니젠 주식회사 엑세나타이드 유사체 및 이의 용도
PE20221595A1 (es) * 2020-01-13 2022-10-10 Hanmi Pharm Ind Co Ltd Uso terapeutico de un conjugado de accion prolongada de un triple agonista que tiene actividad en todos los receptores de glucagon/glp-1/gip para enfermedades pulmonares
CN115463208B (zh) * 2021-10-09 2023-05-30 上海海赜生物科技有限公司 一种口服降糖组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943763B2 (en) * 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
ES2371072T3 (es) * 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
KR100731875B1 (ko) * 2003-07-28 2007-06-25 오츠카 가가쿠 가부시키가이샤 아미노화 복합형 당사슬 유도체 및 그의 제조방법
JP2005095331A (ja) 2003-09-24 2005-04-14 Ihara Suisan Kk 魚皮真皮コラーゲンを含有する発泡体シートおよびその用途
WO2006010143A2 (en) * 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
JPWO2007063907A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
BRPI0813139A8 (pt) * 2007-06-19 2019-01-29 Glytech Inc peptídeo glp-1 com adição de cadeia oligossacarídea

Also Published As

Publication number Publication date
RU2539829C2 (ru) 2015-01-27
JP5646848B2 (ja) 2014-12-24
AU2008264750B2 (en) 2012-07-05
BRPI0813139A8 (pt) 2019-01-29
WO2008155900A1 (ja) 2008-12-24
US20110245166A1 (en) 2011-10-06
US7985731B2 (en) 2011-07-26
AU2008264750A1 (en) 2008-12-24
RU2010101331A (ru) 2011-07-27
US20130345129A1 (en) 2013-12-26
SG178797A1 (en) 2012-03-29
EP2172479A1 (en) 2010-04-07
EP2172479B1 (en) 2016-09-14
KR20100049032A (ko) 2010-05-11
DK2172479T3 (en) 2016-12-19
US20090111739A1 (en) 2009-04-30
JPWO2008155900A1 (ja) 2010-08-26
TW200902068A (en) 2009-01-16
CN102015761A (zh) 2011-04-13
CA2696615A1 (en) 2008-12-24
AU2008264750C1 (en) 2013-01-10
EP2172479A4 (en) 2011-08-24
TWI423821B (zh) 2014-01-21
US8507429B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
NO2021010I1 (no) telostritat ethyl
BRPI0914889A2 (pt) peptídeo glp-1 adicionado de cadeia oligossacarídica
BRPI0813647A2 (pt) Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0811497A2 (pt) Arquitetura multiprocessador com encadeamento otimizado
BRPI0922322A2 (pt) endoscópio com uma porção curvada
EP3450425C0 (en) PERCARBOXYLIC ACID COMPOSITION
BRPI0814587A2 (pt) Peptídeos antibióticos
BRPI0716855A2 (pt) barril
BRPI0813909A2 (pt) Seringa com mecanismo de inutilização
DE602007009238D1 (de) Biplanare elektrode mit sperr-gates
DK3118221T3 (da) Proteiner
DK1849352T3 (da) Mejetærsker
DE602007003533D1 (de) Karosserierahmenbauteil
FI20075738L (fi) Elimen valaiseminen
EP2236266A4 (en) Injector
BRPI0719874A2 (pt) Peptídeos de pth truncados com uma conformação cíclica.
BRPI0919233A2 (pt) conjunto de iluminação portátil
EP2318537A4 (en) OPTIMIZED PROMOTER SEQUENCE
FI20070937A0 (fi) Perhekeinu
DK2276850T3 (da) Irx-2-modificeret fremstillingsfremgangsmåde
HUE038633T2 (hu) MMP-14 specifikus hasítási szekvencia
BRPI0822283A2 (pt) uso de uma composição nutricional
DE502007002482D1 (de) Injektor
BRPI0812584A2 (pt) Composições inseticidas com efeito melhorado
EP2195338A4 (en) N-TERMINAL MODIFIED INTERFERON ALPHA

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GLYTECH, INC. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL